news SARS-CoV-2 mAb cocktail effective against all known variants of virus 8 March 2021 | By Victoria Rees (Drug Target Review) A monoclonal antibody (mAb) cocktail, that targets sites on the Spike protein other than the E484K residue, can neutralise SARS-CoV-2.
news Structure of protein that triggers neurodegeneration isolated and analysed 4 March 2021 | By Victoria Rees (Drug Target Review) Using X-ray crystallography and cryo-electron microscopy, researchers have elucidated the structure of the SARM1 protein, a target for neurodegeneration.
video SARS-CoV-2 vaccines: an interview with Payton Weidenbacher 1 March 2021 | By Victoria Rees (Drug Target Review) DTR's Victoria Rees interviews Payton Weidenbacher from Stanford University, who discusses a new potential SARS-CoV-2 vaccine that the team he works on developed using nanotechnology.
news SARS-CoV-2 model shows Spike protein co-operation 1 March 2021 | By Victoria Rees (Drug Target Review) A new coarse-grained model of the complete SARS-CoV-2 virion has revealed potential new ways to combat the coronavirus.
news Scientists uncover structural biology details of SARS-CoV-2 infection 26 February 2021 | By Victoria Rees (Drug Target Review) Researchers have used computer simulations to model how the SARS-CoV-2 fusion peptide interacts with and penetrates the cell membrane.
news Researchers identify new therapeutic targets on SARS-CoV-2 Spike protein 23 February 2021 | By Victoria Rees (Drug Target Review) Researchers have found that the S1/S2 cleavage of the SARS-CoV-2 Spike protein could be a potential target for COVID-19 therapeutics.
news Analysis conducted on glycan structure from sheep prion strains 22 February 2021 | By Victoria Rees (Drug Target Review) Using liquid chromatography/mass spectrometry, researchers have revealed no major differences in glycan structures in two prion strains.
news D614G Spike mutation makes SARS-CoV-2 up to eight times more infectious 18 February 2021 | By Victoria Rees (Drug Target Review) A study has shown the D614G mutation in the Spike protein of SARS-CoV-2 makes the coronavirus more transmissible than the original virus from China.
news Targeting Nsp1 protein could be a pathway for COVID-19 therapy 17 February 2021 | By Victoria Rees (Drug Target Review) A study has shown that targeting the protein Nsp1 can inhibit genes for viral replication, which could lead to new COVID-19 treatments.
news Mutations in SARS-CoV-2 Spike could lead to greater infectivity, study shows 16 February 2021 | By Victoria Rees (Drug Target Review) Comparing the original SARS-CoV-2 Spike protein with a mutated version, researchers have potentially revealed why the mutated version is dominant.
news Revealed protein structure could aid in Huntington’s disease treatment development 15 February 2021 | By Victoria Rees (Drug Target Review) Using NMR spectroscopy, researchers have partially observed the structure of heat shock proteins that bind to proteins that cause Huntington's disease.
article SARS-CoV-2 and immunology: antibody developments 15 February 2021 | By Victoria Rees (Drug Target Review) Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
news Protein sequences provide insight to SARS-CoV-2 infection, study shows 12 February 2021 | By Victoria Rees (Drug Target Review) Research has shown that ACE2 and several integrins containing SLiMs are involved in SARS-CoV-2 infection, presenting new therapeutic targets.
news Researchers discover factor that triggers muscle stem cells to heal 11 February 2021 | By Victoria Rees (Drug Target Review) In a zebrafish model, researchers have found that the protein NAPMT can trigger muscle stem cells to proliferate and heal muscle damage.
news ProAgio drug shows success against solid tumours in mice 10 February 2021 | By Victoria Rees (Drug Target Review) Studies in mice have shown that the drug ProAgio is effective at treating pancreatic cancer and triple-negative breast cancer.
